Francis Medical

Executive Summary

Francis Medical is a Minneapolis-based private medical device company founded in 2016, developing minimally invasive water vapor ablation systems for urological conditions. Its lead product, the Vanquish System, is FDA-cleared for thermal ablation of targeted prostate tissue, offering a precise, low-morbidity treatment option for localized prostate cancer. The technology uses convective water vapor energy to ablate tissue, preserving surrounding healthy structures. With an initial focus on prostate cancer, Francis Medical aims to address the growing demand for focal therapy alternatives to radical prostatectomy and radiation. The company's platform has potential applications in other urological cancers, such as renal cell carcinoma, which could expand its addressable market. As a private entity, Francis Medical benefits from flexibility in clinical development and strategic partnerships. The Vanquish System's FDA clearance provides a commercial foothold, and ongoing studies are expected to generate long-term efficacy and safety data that could drive adoption. Given the large prostate cancer incidence and the trend toward minimally invasive treatments, Francis Medical is well-positioned in the urology device space.

Upcoming Catalysts (preview)

• Q4 2026Pivotal trial results for renal cell carcinoma (RCC) indication50% success
• Q2 2026Publication of 5-year outcomes from prostate cancer focal therapy study70% success
• Q3 2026Strategic partnership or distribution agreement for Vanquish System in major US urology centers60% success